SR Pharma Completes Name Change to Silence Therapeutics plc
News May 04, 2007
Silence Therapeutics plc has announced that the Company's name change from SR Pharma plc has been completed.
The new company name, Silence Therapeutics, and corporate identity have been put in place to reflect the Company’s core focus on RNAi, a therapeutic approach which seeks to ‘silence’ disease relevant genes.
Silence Therapeutics is developing a broad pipeline of RNAi therapeutics based on its proprietary AtuRNAi molecules and systemic delivery system, AtuPLEX.
Silence Therapeutics’ in-house RNAi therapeutic programmes, which are in late-stage pre-clinical development, are focused on systemic cancer indications such as gastro-intestinal and non-small lung cancer.
In addition, Silence Therapeutics has AtuRNAi molecules in clinical development via its collaborators Quark Biotech and its sublicensee Pfizer.
The Company is now trading under the ticker SLN on the AiM market.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.